Clinical Validation of Breath Analyser Tests for Diagnosis of COVID-19.
Launched by TERA GROUP · Oct 24, 2021
Trial Information
Current as of May 07, 2025
Unknown status
Keywords
ClinConnect Summary
Within this proposed project, the NHS will collect two diagnostic or screening tests per participant. One sample will be used by NHS and be run through regular diagnostics. The second, will be breath sample which will be tested using the BioSafety Technologies Ltd, rapid screening tool. This will use a pre-defined protocol. These tests would then be compared to assess the diagnostic efficacy including sensitivity and specificities. We will be aiming to achieve a significant comparison to ensure certainty and to exploit the information for proposing a novel diagnostic system to enhance capab...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participant is willing and able to give informed consent for participation in the study.
- • Male or Female, aged 18 years or above.
- • Requiring a diagnostic or screening RT-PCR test for COVID-19
- Exclusion Criteria:
- • Subjects under general anaesthesia
- • The inability to personally sign the consent form.
- • The inability to exhale breath
About Tera Group
Tera Group is a leading clinical trial sponsor specializing in innovative healthcare solutions and advanced therapeutic development. With a commitment to enhancing patient outcomes, Tera Group leverages cutting-edge research methodologies and a robust network of clinical sites to facilitate the efficient execution of clinical trials across various therapeutic areas. The organization is dedicated to maintaining the highest standards of regulatory compliance and ethical practices, ensuring that all studies are conducted with integrity and transparency. By fostering collaboration among stakeholders, Tera Group aims to accelerate the translation of scientific discoveries into viable treatment options, ultimately improving the quality of care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ashton Under Lyne, Lancashire, United Kingdom
Patients applied
Trial Officials
Ilan Lieberman, MD
Principal Investigator
Tameside and Glossop Integrated Care NHS England
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials